表紙
市場調查報告書

CAR-T細胞療法的全球市場預測:地區、標的抗原、臨床試驗/研究、企業

CAR T Cell Therapy Market, Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study & Companies

出版商 Renub Research 商品編碼 686995
出版日期 內容資訊 英文 159 Pages
商品交期: 最快1-2個工作天內
價格
CAR-T細胞療法的全球市場預測:地區、標的抗原、臨床試驗/研究、企業 CAR T Cell Therapy Market, Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study & Companies
出版日期: 2018年08月02日內容資訊: 英文 159 Pages
簡介

本報告提供全球CAR-T細胞 (嵌合抗原受體T細胞) 療法市場相關CAR-T細胞療法市場與CAR-T細胞治療研究的2個觀點調查,各地區、標的抗原市場區隔分析,主要的市場成長的推動要素與課題,SWOT分析,法規趨勢,及主要企業簡介等資訊彙整。

第1章 摘要整理

第2章 全球CAR-T細胞療法市場

第3章 市場佔有率:CAR-T細胞療法

  • 各地區
  • 各標的抗原

第4章 標的抗原市場

  • 0CD20
  • CD19
  • GD2
  • GD22
  • CD30
  • CD33
  • HER2
  • Mesothelin (MESO)
  • EGFRvIII
  • 其他

第5章 CAR-T細胞療法:地區市場

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東
  • 非洲

第6章 全球CAR-T細胞療法:臨床試驗/研究

  • CD19
  • CD20
  • CD22
  • CD30
  • CD33
  • EGFRvIII
  • GD2
  • HER1
  • HER2
  • MESO

第7章 中國的CAR-T細胞療法:臨床試驗詳細內容

第8章 SWOT分析

第9章 CAR-T細胞療法的法規

  • 美國
  • EU
  • 中國

第10章 CAR-T細胞療法市場上IPO/投資/資金/聯盟

  • 創業投資投資
  • CAR-T企業的IPO
  • CAR-T企業的聯盟/契約
  • 主要的CAR-T技術的契約

第11章 全球促進因素

  • CAE-T治療的FDA的核准
  • 全球CAR-T試用數激增

第12章 課題

  • 法規的課題
  • 非常高價的CAR-T治療

第13章 Novartis

第14章 Gilead Sciences (Kite Pharma)

第15章 Celgene Corporation (Juno Therapeutics)

第16章 Celyad

目錄

Get Free Customization in This Report.

CAR T Cell therapy market is expected to grow with a CAGR of over 46 percent in the forecast period. Year 2017 has created new milestone for the oncology patients as FDA approved the first two CD19-targeted (Chimeric Antigen Receptor) CAR T cell therapies developed by Novartis and Gilead Sciences/Kite Pharma in the United States. These two approvals will certainly help to boost the global CAR T cell therapy market as more players are looking this big opportunities to enter the market place. At present over 200 CAR T clinical trials are running or completed across various parts of the world.

Rising number of adults and children developing cancer, increasing government initiatives for promoting research for cell therapy in cancer and rising number of clinical trials globally are some of the key drivers for the global CAR T Cell therapy market; however high cost of CAR T cell therapy treatment and regulatory challenges are key inhibitors for this market.

Renub Research latest study report “CAR T Cell Therapy Market Global Forecast by Regions (North America, Europe, Asia Pacific, Latin America, Middle East, Africa), Targeted Antigens (CD19, CD20, GD2, CD22, CD30, CD33, HER2, MESO, EGFRvII, Others) Clinical Trials/Study (CD19, CD20, GD2, CD22, CD30, CD33,HER1, HER2, MESO, EGFRvII) Companies (Novartis,Gilead Sciences (Kite Pharma), Celgene Corporation (Juno Therapeutics), Celyad)” provides a detailed and comprehensive insight of the global CAR T cell therapy market.

This report studies the Global CAR T cell therapy market from 2 key view points by CAR T cell therapy market and CAR T cell therapy studies. Market segments are further studied by geographical regions and targeted antigens whereas CAR T cell therapy studies by targeted antigens globally and China specific. The report provides a complete analysis of the key Growth Drivers and Challenges, SWOT analysis, market, and their projections for the upcoming years (2028).

The report has been analyzed from 9 major viewpoints

  • 1. Targeted Antigen - Global CAR T Cell Therapy Market
  • 2. Regional CAR T Cell Therapy Market
  • 3. Global - CAR T Cell Therapy Clinical Trials/Study
  • 4. China CAR T Cells Clinical Trials Details
  • 5. CAR T Cell Therapy SWOT Analysis
  • 6. The Regulation in CAR T Cell Therapy
  • 7. Global - IPO/Investment/Funding/Partnership in CAR T Cell Therapy Market
  • 8. Growth Drivers and Challenges
  • 9. Key CAR T companies Initiatives and Financial Insight

Targeted Antigens - Global CAR T Cell Therapy Market & Forecast

  • CD19
  • CD20
  • GD2
  • CD22
  • CD30
  • CD33
  • HER2
  • MESO
  • EGFRvII
  • Others

Regional CAR-T Cell Therapy Market & Forecast

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Global - CAR T Cell Therapy Clinical Trials/Study

  • CD19
  • CD20
  • GD2
  • CD22
  • CD30
  • CD33
  • HER1
  • HER2
  • MESO
  • EGFRvII

China CAR T Cells Clinical Trials Details

  • By Cities CAR T Cells Clinical Trials
  • CD19 Directed CAR T Cells Clinical Trials
  • Non-CD19 Directed CAR T Cells Clinical Trials
  • Solid Tumors CAR T Cells Clinical Trials

Client can purchase this report in sections through Purchase by Chapter Tab given above.

The Regulation in CAR T Cell Therapy

  • United States
  • European Union
  • China

IPO/Investment/Funding/Partnership in CAR T Cell Therapy Market

  • Venture Capital Investment
  • Initial Public Offerings
  • Strategic Partnerships/Deals
  • Key CAR T Technology Deals

Key Companies covered in this report are

  • Novartis
  • Gilead Sciences (Kite Pharma)
  • Celgene Corporation (Juno Therapeutics)
  • Celyad

Table of Contents

1. Executive Summary

2. Global Chimeric Antigen Receptor (CAR)-T cell Therapy Market

3. Market Share- CAR-T Cell Therapy

  • 3.1. By Geographical Region
  • 3.2. By Targeted Antigens

4. Targeted Antigen Market

  • 4.1. CD19
    • 4.1.1. Introduction
    • 4.1.2. Market Size and Forecast
  • 4.2. CD20
    • 4.2.1. Introduction
    • 4.2.2. Market Size and Forecast
  • 4.3. GD2
    • 4.3.1. Introduction
    • 4.3.2. Market Size and Forecast
  • 4.4. CD22
    • 4.4.1. Introduction
    • 4.4.2. Market Size and Forecast
  • 4.5. CD30
    • 4.5.1. Introduction
    • 4.5.2. Market Size and Forecast
  • 4.6. CD33
    • 4.6.1. Introduction
    • 4.6.2. Market Size and Forecast
  • 4.7. HER2
    • 4.7.1. Introduction
    • 4.7.2. Market Size and Forecast
  • 4.8. Mesothelin (MESO)
    • 4.8.1. Introduction
    • 4.8.2. Market Size and Forecast
  • 4.9. EGFRvIII
    • 4.9.1. Introduction
    • 4.9.2. Market Size and Forecast
  • 4.10. Others
    • 4.10.1. Market Size and Forecast.

5. Geographical CAR-T Cell Therapy Market (2016-2026)

  • 5.1. North America
  • 5.2. Europe
  • 5.3. Asia Pacific
  • 5.4. Latin America
  • 5.5. Middle East
  • 5.6. Africa

6. Global- CAR-T Cell Clinical Trials/Study

  • 6.1. CD19
  • 6.2. CD20
  • 6.3. CD22
  • 6.4. CD30
  • 6.5. CD33
  • 6.6. EGFRvIII
  • 6.7. GD2
  • 6.8. HER1
  • 6.9. HER2
  • 6.10. MESO

7. China CAR-T Cells Clinical Trials Details

  • 7.1. By Cities CAR-T Cells Clinical Trials
  • 7.2. CD19 Directed CAR-T Cells Clinical Trials
  • 7.3. Non-CD19 Directed CAR-T Cells Clinical Trials
  • 7.4. Solid Tumors CAR-T Cells Clinical Trials

8. CAR-T Cell Therapy SWOT Analysis

  • 8.1. Strength
  • 8.2. Weakness
  • 8.3. Opportunities
  • 8.4. Threats

9. Regulation in CAR-T Cell Therapy

  • 9.1. United States
  • 9.2. European Union
  • 9.3. China

10. IPO/Investment/Funding/Partnership in CAR-T Cell Therapy Market

  • 10.1. Venture Capital Investment
  • 10.2. Initial Public Offerings of CAR-T Companies
  • 10.3. CAR-T Companies Strategic Partnerships/Deals
  • 10.4. Key CAR-T Technology Deals

11. Growth Drivers

  • 11.1. FDA Approvals of CAR-T Therapy
  • 11.2. Dramatically Increasing Number of CAR-T Cell Trials Globally

12. Challenges

  • 12.1. Regulatory Challenges
  • 12.2. Very Expensive CAR-T Therapy Treatment

13. Novartis

  • 13.1. Company Overview
  • 13.2. Initiatives
    • 13.2.1. Point 1
    • 13.2.2. Point 2
  • 13.3. Financial Insight

14. Gilead Sciences (Kite Pharma)

  • 14.1. Company Overview
  • 14.2. Company Initiatives
    • 14.2.1. Point 1
    • 14.2.2. Point 2
    • 14.2.3. Point 3
  • 14.3. Company Financial Insight

15. Celgene Corporation (Juno Therapeutics)

  • 15.1. Company Overview
  • 15.2. Company Initiatives
    • 15.2.1. Point 1
    • 15.2.2. Point 2
  • 15.3. Company Financial Insight

16. Celyad

  • 16.1. Company Overview
  • 16.2. Company Initiatives
    • 16.2.1. Point 1
    • 16.2.2. Point 2
  • 16.3. Financial Insight

List of Figures:

  • Figure 2-1: Global - CAR-T Cell Therapy Market & Forecast (Million US$), 2017 - 2028
  • Figure 3-1: Global - Current & Forecast for CAR-T Cell Therapy Regional Market Share (Percent), 2017 - 2028
  • Figure 4-1: Global - Current & Forecast for CD19 Antigen CAR-T Cell Therapy Market (Million US$), 2017 - 2028
  • Figure 4-2: Global - Current & Forecast for CD20 Antigen CAR-T Cell Therapy Market (Million US$), 2017 - 2028
  • Figure 4-3: Global - Current & Forecast for GD2 Antigen CAR-T Cell Therapy Market (Million US$), 2017 - 2028
  • Figure 4-4: Global - Current & Forecast for CD22 Antigen CAR-T Cell Therapy Market (Million US$), 2017 - 2028
  • Figure 4-5: Global - Current & Forecast for CD30 Antigen CAR-T Cell Therapy Market (Million US$), 2017 - 2028
  • Figure 4-6: Global - Current & Forecast for CD33 Antigen CAR-T Cell Therapy Market (Million US$), 2017 - 2028
  • Figure 4-7: Global - Current & Forecast for HER2 Antigen CAR-T Cell Therapy Market (Million US$), 2017 - 2028
  • Figure 4-8: Global - Current & Forecast for MESO Antigen CAR-T Cell Therapy Market (Million US$), 2017 - 2028
  • Figure 4-9: Global - Current & Forecast for EGFRvIII Antigen CAR-T Cell Therapy Market (Million US$), 2017 - 2028
  • Figure 4-10: Global - Current & Forecast for Others Antigen CAR-T Cell Therapy Market (Million US$), 2017 - 2028
  • Figure 5-1: North America - Current & Forecast for CAR-T Cell Therapy Market (Million US$), 2017 - 2028
  • Figure 5-2: Europe - Current & Forecast for CAR-T Cell Therapy Market (Million US$), 2017 - 2028
  • Figure 5-3: Asia Pacific - Current & Forecast for CAR-T Cell Therapy Market (Million US$), 2017 - 2028
  • Figure 5-4: Latin America - Current & Forecast for CAR-T Cell Therapy Market (Million US$), 2017 - 2028
  • Figure 5-5: Middle East - Current & Forecast for CAR-T Cell Therapy Market (Million US$), 2017 - 2028
  • Figure 5-6: Africa - Current & Forecast for CAR-T Cell Therapy Market (Million US$), 2017 - 2028
  • Figure 7-1: China - By Cities CAR-T Cells Clinical Trials (Number), 2017
  • Figure 11-1: Global - CAR-T New & Total Clinical Trials (Number), 2012-2017
  • Figure 11-2: Global - By Phase CAR-T Clinical Trials (Number), 2017
  • Figure 13-1: Novartis - Global Sales (Million US$), 2013 - 2017
  • Figure 13-2: Novartis - Forecast for Global Sales (Million US$), 2018 - 2028
  • Figure 14-1: Gilead Sciences - Global Sales (Million US$), 2013 - 2017
  • Figure 14-2: Gilead Sciences - Forecast for Global Sales (Million US$), 2018 - 2028
  • Figure 15-1: Celgene - Global Sales (Million US$), 2013 - 2017
  • Figure 15-2: Celgene - Forecast for Global Sales (Million US$), 2018 - 2028
  • Figure 16-1: Celyad - Global Sales (Million US$), 2013 - 2017
  • Figure 16-2: Celyad - Forecast for Global Sales (Million US$), 2018 - 2028

List of Tables:

  • Table 3-1: Global - Current & Forecast for CAR-T Cell Therapy Targeted Antigens Market Share (Percent), 2017 - 2028
  • Table 6-1: Global - Details of CD19 CAR-T Studies, 2018
  • Table 6-2: Global - Details of CD20 CAR-T Studies, 2018
  • Table 6-3: Global - Details of CD22 CAR-T Studies, 2018
  • Table 6-4: Global - Details of CD30 CAR-T Studies, 2018
  • Table 6-5: Global - Details of CD33 CAR-T Studies, 2018
  • Table 6-6: Global - Details of EGFRvIII CAR-T Studies, 2018
  • Table 6-7: Global - Details of GD2 CAR-T Studies, 2018
  • Table 6-8: Global - Details of HER1 CAR-T Studies, 2018
  • Table 6-9: Global - Details of HER2 CAR-T Studies, 2018
  • Table 6-10: Global - Details of MESO CAR-T Studies, 2018
  • Table 7-1: China - CD19 Directed CAR-T Cells Clinical Trials, 2017
  • Table 7-2: China - Non-CD19 Directed CAR-T Cells Clinical Trials, 2017
  • Table 7-3: China - Solid Tumors CAR-T Cells Clinical Trials, 2017
  • Table 10-1: Global - Venture Capital Investments (Million US$) in CAR-T Cell Therapy, 2011 - 2017
  • Table 10-2: Global - Initial Public Offerings (Million US$) in CAR-T Cell Therapy, 2011 - 2016
  • Table 10-3: Global - CAR-T Companies Strategic Partnerships/Acquisitions, 2012-2017
  • Table 10-4: Global - Key CAR-T Technology Deals, 2012-2017